Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DALG29
|
|||
| Drug Name |
KY1044
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Kymab
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inducible T-cell costimulator (ICOS) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03829501) Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Kymab. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.